Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROBE-IT
NCT02973594Phase 4Completed
- Sponsor
- University of Colorado Denver
- Start
- Nov 2016
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in heart failure with reduced ejection fraction (HFrEF) and idiopathic dilated cardiomyopathy (IDC) comparing Ivabradine with Placebo (2 arms). Primary endpoint: Left ventricular reverse remodeling according to heart rate response at 24 weeks. Started Nov 2016; status: completed.
02
Drugs
ivabradine
03
Conditions
heart failure with reduced ejection fraction (HFrEF)idiopathic dilated cardiomyopathy (IDC)
Beyond the preview
Go deeper on NCT02973594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02973594.